Table III.

Univariate and multivariate Cox regression analysis in each cohort.

A, Training cohort (n=264)
	Univariate analysis			Multivariate analysis
Variables	HR	95% CI of HR	P-value	HR	95% CI of HR	P-value
Five-lncRNA risk score (high/low risk)	2.743	1.792–4.200	<0.001	2.418	1.566–3.736	<0.001
Age (≥65/<65 years)	1.006	0.680–1.490	0.975	1.013	0.681–1.508	0.949
Sex (female/male)	1.078	0.724–1.603	0.712	1.026	0.682–1.542	0.903
Stage
(II vs. I)	3.028	1.855–4.943	<0.001	2.583	1.568–4.253	<0.001
(III/IV vs. I)	2.837	1.774–4.537	<0.001	2.517	1.563–4.054	<0.001
B, Verification cohort (n=222)
	Univariate analysis			Multivariate analysis
Variables	HR	95% CI of HR	P-value	HR	95% CI of HR	P-value
Five-lncRNA risk score (high/low risk)	1.962	1.232–3.127	0.005	1.925	1.201–3.085	0.007
Age (≥65/<65 years)	1.369	0.860–2.181	0.185	1.442	0.886–2.283	0.145
Sex (female/male)	0.734	0.468–1.150	0.177	0.819	0.521–1.288	0.388
Stage
(II vs. I)	1.655	0.944–2.902	0.079	1.692	0.948–3.020	0.075
(III/IV vs. I)	4.297	2.458–7.429	<0.001	4.515	2.571–7.929	<0.001
Total cohort (n=486)
	Univariate analysis			Multivariate analysis
Variables	HR	95% CI of HR	P-value	HR	95% CI of HR	P-value
Five-lncRNA risk score (high/low risk)	2.225	1.636–3.027	<0.001	2.117	1.550–2.891	<0.001
Age (≥65/<65 years)	1.147	0.851–1.547	0.368	1.198	0.887–1.619	0.239
Sex (female/male)	0.909	0.677–1.220	0.524	0.915	0.680–1.232	0.559
Stage
(II vs. I)	2.318	1.606–3.347	<0.001	2.204	1.520–3.197	<0.001
(III/IV vs. I)	3.371	2.370–4.795	<0.001	3.284	2.301–4.687	<0.001

HR, hazard ratio; lncRNA, long non-coding RNA.